/

MGTX

MeiraGTx Holdings plcClosed

9.94−0.44 −4.24%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delayAfter hours 9.95 +0.10%

Open

10.26

Prev close

10.38

Day range

9.8610.39

52-week range

6.6215.35

Volume

1.12M1.46×

Mkt cap

954.67M

P/E ttm

11.04

Fwd P/E

-6.52

EPS ttm

0.9000

Div yield

0.00%

Earnings

Aug 13, 2026

From 52w high

−35.24%

Price Chart

Yahoo Finance · delayed

MGTXOct 12, 2026O 10.69H 10.76L 10.32C 10.38−0.31 (−2.90%)Vol 506.50K

SMA 5012.73
SMA 20010.17

1Y change +32.40% since Oct 10, 2025 close538 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

MGTX MeiraGTx Holdings plc · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −4.95%
1 month: −18.84%
3 months: −15.88%
6 months: +7.79%
Year to date: +30.57%
1 year: +32.40%

Valuation & ownership

Market cap: 954.67M
Enterprise value: 924.03M
P/E (ttm): 11.04
Forward P/E: -6.52
PEG ratio: —
Price / book: 4.34
Price / sales (ttm): 2.40
EV / EBITDA: 4.71
EPS (ttm): 0.9000
EPS (forward): -1.53
Beta (5y monthly): 1.35
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 96.04M
Float: 53.77M
Short % of float: 8.71%
Short ratio (days): 6.35
Held by insiders: 16.33%
Held by institutions: 70.51%
Avg volume (3m): 769.98K
50-day average: 12.73
200-day average: 10.17
52-week change: +32.40%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 30.9
vs 50-day SMA: −18.44%
vs 200-day SMA: +2.03%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 5.58%
Realised vol (20d, ann.): 42.3%
From 52-week high: −32.38%
From 52-week low: +56.80%

ANR

Analyst Consensus

8 analysts

Consensus

—

Mean target

27.75

+179.18% implied

Low 16.00Median 23.50High 50.00

Recommendation trend

Now7 / 1 / 0
1m ago7 / 0 / 0

DES

About MeiraGTx Holdings plc

Yahoo Finance profile

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.

Sector: Healthcare
Industry: Biotechnology
Employees: 393
Headquarters: New York, NY, United States

SEAS

Seasonality · MGTX

2018–2026 · monthly returns

Strongest month Oct +8.77%Weakest month Mar −8.11%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-4.3	-0.7	14.6	6.5	15.5	26.9	-12.7	17.1	-20.3	-9.6			+25.0%
2025	3.3	13.4	-4.9	4.6	-27.8	27.3	17.3	-4.6	12.7	10.3	-8.6	-4.2	+30.5%
2024	-13.5	1.6	-1.6	-19.6	0.4	-14.1	24.2	-22.2	2.5	32.9	22.2	-10.0	−13.2%
2023	28.2	-7.7	-33.0	3.5	28.6	-2.3	-6.2	-0.2	-21.9	-7.9	15.5	34.5	+7.7%
2022	-36.9	-4.4	-3.3	-25.7	-18.5	-9.8	9.4	0.2	1.3	-13.6	-15.3	5.8	−72.5%
2021	-5.4	3.6	-2.8	3.8	-7.9	12.4	-9.7	-10.6	5.4	63.1	-17.8	34.3	+56.8%
2020	-9.5	-10.5	-17.0	2.5	7.8	-15.6	3.8	0.2	1.8	-3.5	10.5	7.2	−24.4%
2019	28.4	31.3	6.0	13.3	12.7	22.1	1.4	-25.7	-21.2	-9.4	33.4	3.9	+107.7%
2018							-19.6	26.4	16.8	-1.8	1.1	-28.6	−15.9%

INSD

Insider Activity · MGTX

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

655.1K shares

Sells, 6 months

291.3K shares

Net shares

+363.7K

Net change in insider shares

+2.40%

Date	Insider	Transaction	Shares	Value
Oct 5, 2026	Naylor StuartOfficer	Sale at price 10.64 per share.	27.7K	$294.29K
Aug 17, 2026	Forbes AlexandriaChief Executive Officer	Sale at price 13.86 per share.	62K	$859.32K
Jul 20, 2026	Giroux RichardChief Operating Officer	Sale at price 12.51 per share.	56K	$700.56K
Jul 6, 2026	Naylor StuartOfficer	Sale at price 13.86 - 14.90 per share.	27.7K	$409.47K
Jun 9, 2026	Harris Keith RDirector	—	75K	—
May 26, 2026	Giroux RichardChief Operating Officer	Stock Gift at price 0.00 per share.	7K	—
May 18, 2026	Forbes AlexandriaChief Executive Officer	Sale at price 9.17 per share.	62K	$568.54K
Apr 20, 2026	Giroux RichardChief Operating Officer	Sale at price 10.22 per share.	56K	$572.32K
Apr 16, 2026	Perceptive Advisors, L.L.C.Beneficial Owner of more than 10% of a Class of Security	Stock Award(Grant) at price 9.00 per share.	555.6K	$5.00M
Apr 6, 2026	Naylor StuartOfficer	Sale at price 9.36 per share.	27.7K	$258.91K
Mar 23, 2026	Forbes AlexandriaChief Executive Officer	Sale at price 7.41 per share.	62K	$459.42K
Feb 19, 2026	Naylor StuartOfficer	—	25K	—
Feb 19, 2026	Wollin Robert JGeneral Counsel	—	11.3K	—
Feb 19, 2026	Forbes AlexandriaChief Executive Officer	—	62.5K	—
Feb 19, 2026	Zeldin Robert KOfficer	—	7.5K	—
Feb 19, 2026	Giroux RichardChief Operating Officer	—	60K	—
Jan 15, 2026	Naylor StuartOfficer	—	75K	—
Jan 15, 2026	Wollin Robert JGeneral Counsel	—	50K	—
Jan 15, 2026	Forbes AlexandriaChief Executive Officer	—	310K	—
Jan 15, 2026	Zeldin Robert KOfficer	—	35K	—

MGTX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

MGTX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About MeiraGTx Holdings plc

Seasonality · MGTX

Insider Activity · MGTX

Congress Trades · MGTX

Investors Holding MGTX

Investors Holding MGTX

Congress Trades · MGTX

Seasonality · MGTX

Insider Activity · MGTX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About MeiraGTx Holdings plc

Financial Snapshot

Earnings & Dividends

News